SC
DGX icon

Savant Capital’s Quest Diagnostics DGX Stock Holding History

Savant Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
61,498
+57,889
+1,604% +$11.4M 0.04% 243
2026
Q1 		$707K Buy
3,609
+326
+10% +$63.3K ﹤0.01% 752
2025
Q4 		$570K Buy
3,283
+615
+23% +$112K ﹤0.01% 786
2025
Q3 		$508K Buy
2,668
+639
+31% +$113K ﹤0.01% 793
2025
Q2 		$364K Buy
2,029
+349
+21% +$60.6K ﹤0.01% 878
2025
Q1 		$284K Sell
1,680
-10,273
-86% -$1.69M ﹤0.01% 862
2024
Q4 		$1.8M Buy
11,953
+9,467
+381% +$1.47M 0.01% 467
2024
Q3 		$386K Buy
+2,486
New +$371K ﹤0.01% 986
2023
Q2 		– Sell
-2,246
Closed -$318K – 796
2023
Q1 		$318K Buy
2,246
+439
+24% +$62.8K 0.01% 584
2022
Q4 		$283K Sell
1,807
-409
-18% -$58.8K 0.01% 477
2022
Q3 		$272K Sell
2,216
-723
-25% -$95.2K 0.01% 448
2022
Q2 		$391K Buy
2,939
+388
+15% +$52.9K 0.01% 384
2022
Q1 		$349K Buy
2,551
+1,048
+70% +$146K 0.01% 423
2021
Q4 		$260K Buy
+1,503
New +$229K 0.01% 477

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Savant Capital's DGX Position: Q2 2026 in Review

Savant Capital increased its Quest Diagnostics (DGX) stake by 1,604% in Q2 2026, buying an estimated $11.4M and bringing the position to 61,498 shares worth $14.1M. The position accounts for 0.04% of the portfolio, ranked #243.

Savant Capital first reported a position in DGX in Q4 2021 and has held it in 14 quarters since. 1,105 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Savant Capital held 61,498 shares of Quest Diagnostics worth $14.1M as of Q2 2026.
  • Savant Capital bought 57,889 Quest Diagnostics shares in Q2 2026, an estimated $11.4M.
  • Quest Diagnostics made up 0.04% of Savant Capital's portfolio in Q2 2026, its #243 holding.
  • Savant Capital first reported a position in Quest Diagnostics in Q4 2021 and has held it in 14 quarters since.
  • 1,105 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.